

1 **Limited specificity of SARS-CoV-2 antigen-detecting rapid diagnostic tests at**
2 **low temperatures**

3

4 Verena Haage¹, Andres Moreira-Soto¹, Jilian A. Sacks², Victor Corman^{1,3}, Christian
5 Drosten^{1,3}, Felix Drexler^{1,3}

6

7 ¹Institute of Virology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie
8 Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health,
9 Berlin, Germany

10 ² Foundation for Innovative New Diagnostics (FIND), Geneva, Switzerland

11 ³ German Centre for Infection Research (DZIF), Associated Partner Charité-
12 Universitätsmedizin Berlin, Berlin, Germany

13

14 *Correspondence: Jan Felix Drexler, Helmut-Ruska-Haus, Institute of Virology,
15 Campus Charité Mitte, Charitéplatz 1, 10098 Berlin, Germany; Email:

16 felix.drexler@charite.de

17

18

19 **Keywords:** SARS-CoV-2, rapid antigen tests, specificity, temperature stability,
20 diagnostics, cold settings

21

22

23

24

25

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

26

27 **Abstract**

28 SARS-CoV-2 antigen-detecting rapid diagnostic tests (Ag-RDTs) are available within
29 and outside of health care settings to enable increased access to COVID-19 diagnosis.
30 These environments include provisional testing facilities, lacking temperature control;
31 as outside temperatures fall, recommended testing temperatures cannot be
32 guaranteed. We report impaired specificity in two out of six Ag-RDTs when used at 2-
33 4°C, indicating that testing in cold settings might cause false-positive results potentially
34 entailing unwarranted quarantine assignments and incorrect incidence estimates.

35

36 **Introduction**

37 SARS-CoV-2 antigen-detecting tests were introduced into the global market during late
38 2020 and are now widely used, in both the global north and south. Many regions
39 located in the northern hemisphere such as the United States or Europe are currently
40 severely affected by the second wave of the COVID-19 pandemic (1, 2). To manage
41 testing demand many physicians, healthcare and public health systems have opened
42 external testing stations such as `diagnostic streets´ or drive-through facilities in urban
43 settings (3). In Berlin, a German metropolis with a population of about 3.5 million
44 inhabitants, several outside testing stations in tents or pavilions are in use, produced
45 by manufacturers who offer special corona test cabins (4). These facilities are often of
46 provisional nature, for example in the form of unheated tents. In the winter months,
47 temperatures in Europe or the U.S. can range from -10°C to 10°C (5, 6), well below
48 the recommended operating temperatures of most Ag-RDTs. Most manufacturers of
49 SARS-CoV-2 Ag-RDTs specify storage conditions between 2-30°C, but stipulate that
50 tests be equilibrated to room temperature (15-30°C) at the time of use to guarantee
51 their performance. With temperatures around freezing point during the winter months,
52 unheated testing facilities cannot always comply with these conditions. Moreover, as

53 the national COVID-19 reference laboratory in Germany, we were contacted by
54 physicians from two German metropolises both reporting an unusual high number of
55 positive SARS-CoV-2 Ag-RDTs from outside testing facilities. To test whether
56 operation of SARS-CoV-2 Ag-RDTs at low outside temperatures impacts their
57 performance, we selected six (**Table 1**) out of the 139 currently commercially available
58 SARS-CoV-2 Ag-RDTs (7) based on clinical performance data (8) and market
59 availability, for validation of specificity when stored and/or operated at cold outside
60 temperatures of 2-4°C.

61

62 **Materials and Methods**

63 Tested conditions included: (a) storage and testing of Ag-RDTs at recommended
64 conditions (15-30°C); (b) storage of tests at recommended conditions, pre-incubation
65 of tests for 30mins to cold-temperatures (2-4°C) and testing at cold temperatures (2-
66 4°C); and (c) storage of tests at 2-4°C followed by testing at 2-4°C (**Figure 1A**).

67 Analytical specificity was examined by testing for cross-reactivity with common cell
68 culture-derived respiratory viruses including the ubiquitous human coronaviruses
69 (HCoV) HCoV-229E (2.9×10^7 copies/ml), HCoV-OC43 (1.0×10^6 copies/ml), influenza
70 virus A H1N1 (7.8×10^6 copies/ml) and rhinovirus A (2.2×10^6 copies/ml). Concentrations
71 were selected according to the guidelines on analytical specificity testing for SARS-
72 CoV-2 Ag-RDTs published by the German Federal Institute for Vaccines and
73 Biomedicines (9). 20 µl of viral cell culture supernatant were added to proprietary lysis
74 buffer or as an internal control, and 20 µl of lysis buffer were directly applied to test
75 cassettes for validation experiments. Tests were performed in duplicates, according to
76 the test-specific supplier instructions for use and results were scored independently by
77 two persons. We additionally tested ten healthy laboratory members who previously
78 volunteered for a SARS-CoV-2 Ag-RDT validation study (8). Healthy volunteers were

79 without symptoms of respiratory tract infection and tested negative for SARS-CoV-2
80 by RT-qPCR (10). All subjects received instructions on self-sampling, swabs were
81 immediately dissolved in 1ml PBS and 20 μ l of PBS were added to proprietary buffer
82 for testing. In a recent study, self-sampling was shown to be a reliable alternative to
83 professional nasopharyngeal swabs for Ag-RDTs (11).

84

85 **Results**

86 Two of the six SARS-CoV-2 Ag-RDTs showed impaired specificity (**Figure 1B**) when
87 stored at room temperature, but exposed to 2-4 $^{\circ}$ C for 30 minutes prior to testing at 2-
88 4 $^{\circ}$ C as cross-reactivity with common respiratory viruses, and false-positive results
89 occurred in healthy volunteers in the form of weak, but clearly visible bands (**Figure**
90 **1C**). In one test (test I), unspecific reactivity was only observed upon short-term
91 incubation at 2-4 $^{\circ}$ C followed by test operation at 2-4 $^{\circ}$ C, but not after long-term storage
92 at 2-4 $^{\circ}$ C. In contrast, the other test yielding unspecific results (test II) yielded almost
93 identically unspecific results after both, short- and long-term storage at 2-4 $^{\circ}$ C and
94 operation at 2-4 $^{\circ}$ C (**Figure 1B**). On the one hand, those data highlight differences
95 between test devices. On the other hand, our results may hint at effects of relatively
96 rapid temperature changes on some tests for unknown reasons, potentially including
97 environmental factors such as condensation. Results were reproducible and
98 functionality of tests was confirmed by determining their level of detection using serial
99 dilutions of SARS-CoV-2 nucleoprotein (SARS-CoV-2-N) at recommended conditions
100 as previously described (8).

101

102 **Discussion**

103 Our study highlights that specificity of SARS-CoV-2 Ag-RDTs may be impaired when
104 operating tests at temperatures that differ from recommended conditions (15-30 $^{\circ}$ C),

105 leading to false-positive results. These results were observed for only certain test
106 brands including one of the Ag-RDT currently listed for emergency use by the World
107 Health Organization (12, 13), highlighting that each test may need to be considered
108 specifically and broader validation of temperature robustness of SARS-CoV-2 RDTs
109 should be performed. Moreover, impaired sensitivity of SARS-CoV-2 Ag-RDTs at
110 elevated temperatures has been reported previously (14), highlighting the importance
111 of test operation at recommended temperatures. Of note, all tests studied here were
112 shown to be highly specific when operated at recommended conditions in prior studies
113 (8, 14), underlining that impaired specificity is not a test-intrinsic problem but owed to
114 test operation under conditions beyond those defined by the manufacturer.

115 Our data imply that caution must be taken when offering SARS-CoV-2 Ag-RDT
116 diagnostics in settings lacking temperature control, including diagnostic streets or
117 drive-through testing stations in car parks (3). Especially under provisional conditions
118 when minimally-trained or unexperienced staff perform diagnostic tests, the
119 establishment of laboratory workflows and compliance with the conditions
120 recommended by the manufacturer are vital to ensure accurate testing (15). Until
121 January 14th 2021, severity of regional lockdown measures in Germany is increased
122 upon trespassing 7-day incidences of 200 per 100.000 inhabitants (16), highlighting
123 the potential consequences of false-positive test results beyond potentially
124 unwarranted individual quarantine assignments, if those results were reported to public
125 health authorities without confirmation by a gold standard test such as RT-PCR (10).

126

127

128

129

130

131 **Funding**

132 The study was partially supported by the Foundation for Innovative New Diagnostics
133 (FIND), including procurement of some test kits. The findings and conclusions
134 contained within are those of the authors and do not necessarily reflect positions or
135 policies of FIND.

136

137 **Conflict of interest:** The authors declare no conflict of interest.

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157 **Table 1. Overview of SARS-CoV-2 rapid antigen tests included in the study**

ID	Test	Manufacturer	Lot No.
I	Panbio™ COVID-19 Ag Rapid Test	Abbott Laboratories	41ADF012A
II	ActivXpress + COVID-19 Antigen Complete Testing Kit	Edinburgh Genetics	AG20200905
III	COVID-19 Ag	Genedia	643X2005
IV	ichroma - COVID-19 Ag	Boditech Med	SRQHA27
V	COVID-19 Antigen Rapid Test Kit	JOYSBIO (Tianjin) Biotechnology Co., Ltd.	2020092409
VI	SARS-CoV-2 Rapid Antigen Test	Roche Diagnostics*	QCO3020083 QCO390003I/Sub:I-2 QCO390011A/Sub:A-2

158 * equals STANDARD Q COVID-19 Test by SD Biosensor, Inc.

159

160

161

162

163

164

165

166

167


168

169

170

171

172



173
 174 **Figure 1. Experimental setup and results for specificity testing of SARS-CoV-2**
 175 **Ag-RDTs. A.** (a): storage and operation at recommended conditions; (b):
 176 recommended storage, pre-incubation at 2-4°C for 30mins and operation at 2-4°C; (c):
 177 storage and operation at 2-4°C. **B.** Specificity of SARS-CoV-2 Ag-RDTs decreases at
 178 low temperatures. (a): rt storage- rt testing; (b): rt storage – 2-4°C 30 min pre-
 179 incubation – 2-4°C testing; (c): 2-4°C storage – 2-4°C testing. red: positive; white:
 180 negative; salmon: weak band, result unclear. rt: room temperature. I: Abbott; II:
 181 ActivXpress; III: Genedia; IV: ichroma; V: JOYSBIO; VI: Roche. **C.** Example for
 182 observed cross-reactivity of the ActivXpress test with Influenza virus A H1N1 and
 183 SARS-CoV-2 nucleoprotein as positive control (SARS-CoV-2-N; 5µg/ml) when tested
 184 under condition (b): recommended storage, pre-incubation at 2-4°C for 30mins and
 185 operation at 2-4°C.

186 References

- 187
188 1. <https://coronavirus.jhu.edu/us-map>. Accessed 14.01.2021.
189 2. <https://www.ecdc.europa.eu/en/cases-2019-ncov-eueea>. Accessed 14.01.2021.
190 3. Shah A, Challener D, Tande AJ, Mahmood M, O'Horo JC, Berbari E, Crane SJ. 2020. Drive-
191 Through Testing: A Unique, Efficient Method of Collecting Large Volume of Specimens During
192 the SARS-CoV-2 (COVID-19) Pandemic. *Mayo Clinic Proceedings* 95:1420-1425.
193 4. https://www.dwd.de/DE/wetter/vorhersage_aktuell/berlin_brandenburg/vhs_bbb_node.html.
194 Accessed 11.01.2021.
195 5. <https://climate.copernicus.eu/european-temperature>. Accessed 14.01.2021.
196 6. [https://www.ncdc.noaa.gov/climate-information/statistical-weather-and-climate-](https://www.ncdc.noaa.gov/climate-information/statistical-weather-and-climate-information)
197 [information](https://www.ncdc.noaa.gov/climate-information/statistical-weather-and-climate-information). Accessed 14.01.2021.
198 7. <https://www.finddx.org/covid-19/pipeline>. Accessed 13.01.2021.
199 8. Corman VM, Haage VC, Bleicker T, Schmidt ML, Mühlemann B, Zuchowski M, Jó Lei WK,
200 Tscheak P, Möncke-Buchner E, Müller MA, Krumbholz A, Drexler JF, Drosten C. 2020.
201 Comparison of seven commercial SARS-CoV-2 rapid Point-of-Care Antigen tests. medRxiv
202 doi:10.1101/2020.11.12.20230292:2020.11.12.20230292.
203 9. Sinne ABMfS-C-Ai, Antigen Schnelltests. vAST.
204 10. Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DK, Bleicker T, Brünink S,
205 Schneider J, Schmidt ML, Mulders DG, Haagmans BL, van der Veer B, van den Brink S,
206 Wijsman L, Goderski G, Romette J-L, Ellis J, Zambon M, Peiris M, Goossens H, Reusken C,
207 Koopmans MP, Drosten C. 2020. Detection of 2019 novel coronavirus (2019-nCoV) by real-
208 time RT-PCR. *Eurosurveillance* 25:2000045.
209 11. Lindner AK, Nikolai O, Kausch F, Wintel M, Hommes F, Gertler M, Krüger LJ, Gaeddert M,
210 Tobian F, Lainati F, Köppel L, Seybold J, Corman VM, Drosten C, Hofmann J, Sacks JA,
211 Mockenhaupt FP, Denkinger CM. 2020. Head-to-head comparison of SARS-CoV-2 antigen-
212 detecting rapid test with self-collected anterior nasal swab versus professional-collected
213 nasopharyngeal swab. medRxiv doi:10.1101/2020.10.26.20219600:2020.10.26.20219600.
214 12. https://www.who.int/diagnostics_laboratory/eual/listing/en/. Accessed 14.01.2021.
215 13. https://www.who.int/diagnostics_laboratory/200922_eul_sars_cov2_product_list.pdf?ua=1.
216 Accessed 14.01.2021.
217 14. Haage V, de Oliveira-Filho EF, Moreira-Soto A, Kühne A, Fischer C, Sacks J, Corman VM,
218 Müller MA, Drosten C, Drexler JF. 2021. Impaired performance of SARS-CoV-2 antigen-
219 detecting rapid tests at elevated temperatures. medRxiv
220 doi:10.1101/2021.01.06.21249314:2021.01.06.21249314.
221 15. Fischer C, Mögling R, Melidou A, Kühne A, Oliveira-Filho EF, Wolff T, Reiche J, Broberg E,
222 Meijer A, Leitmeyer K, Drexler JF, Reusken C. 2020. Variable sensitivity in molecular detection
223 of SARS-CoV-2 in European Expert Laboratories: External Quality Assessment, June - July
224 2020. *J Clin Microbiol* doi:10.1128/jcm.02676-20.
225 16. [https://www.bundesregierung.de/breg-de/themen/coronavirus/corona-massnahmen-](https://www.bundesregierung.de/breg-de/themen/coronavirus/corona-massnahmen-1734724)
226 [1734724](https://www.bundesregierung.de/breg-de/themen/coronavirus/corona-massnahmen-1734724). Accessed 14.01.2021.

227